Emerging studies suggest Retatru tide , a dual agonist targeting both GLP-1 and another hormone, may provide a notable step forward for body management . Initial human trials have shown impressive losses in body tissue, possibly outperforming other obesity treatments. Despite this, more assessment is needed to fully assess its lasting impact and sa